December 16, 2024 01:08 PM EST
Pharma
FDA+

HRSA push­es back against an­oth­er 340B re­bate mod­el, this time from Sanofi

Katherine Lewin

News Reporter

The US Health Re­sources and Ser­vices Ad­min­is­tra­tion on Fri­day warned Sanofi against im­ple­ment­ing its planned re­bate mod­el for some of its out­pa­tient drugs un­der the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Bio­haven’s pro­tein de­grad­er cuts an­ti­bod­ies by 60%

Check­point wins FDA ap­proval of check­point in­hibitor in ad­vanced skin can­cer, seeks part­ner for launch

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

A service from the Financial Times